Skip to main content
Key Specialties
Anesthesiology Cardiology Dermatology Diabetology Endocrinology Gastroenterology General Medicine Geriatrics Hematology Infectious Diseases Internal Medicine Nephrology Neurology Obstetrics and Gynecology Oncology Pediatrics Psychiatry Radiology Respiratory Medicine Rheumatology Surgery Urology
Congress Coverage
2024 ESMO Congress 2024 ERS Congress 2024 EASD Congress 2024 ESC Congress 2024 EAN Congress 2024 ASCO Annual Meeting 2024 ACC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote series | Spotlight on menopause

Menopause can have a significant impact on the body, with effects ranging beyond the endocrine and reproductive systems. Learn about the systemic effects of menopause, so you can help patients in your clinics through the transition.

Published: Thursday 12th December 2024
ADVANCED SEARCH
Log in
Top
Journal of Translational Medicine
Published in:

Open Access 01-12-2024 | Thyroid Cancer | Review

Association of radiomic features with genomic signatures in thyroid cancer: a systematic review

Authors: Neila Luciano, Francesca Maria Orlandella, Mariantonia Braile, Carlo Cavaliere, Marco Aiello, Monica Franzese, Giuliana Salvatore

Published in: Journal of Translational Medicine | Issue 1/2024

Login to get access

Abstract

Background

There is a growing interest on the association of radiomic features with genomic signatures in oncology. Using computational methods, quantitative radiomic data are extracted from various imaging techniques and integrated with genomic information to construct predictive models aimed at advancing diagnostic strategies in cancer patient management. In this context, the aim of this systematic review was to assess the current knowledge on potential application of this association in patients with thyroid cancer (TC).

Methods

A comprehensive literature review was conducted by querying three different databases (PubMed, Scopus and Embase) to identify studies published until June 2024, focusing on the potential association of radiomics and genomics in patients with TC. Pertinent data were subsequently extracted, and the methodological quality was evaluated using the A MeaSurement Tool to Assess Systematic Reviews 2 (AMSTAR 2).

Results

From the initial analysis, a total of 853 papers were identified. After removing duplicates and applying eligibility criteria, we ultimately evaluated 7 articles. It was observed that the most commonly utilized imaging technique for TC examination was ultrasound (US), followed by computed tomography and magnetic resonance imaging. Regarding genomic techniques, sequencing and polymerase chain reaction were the most commonly employed methods to validate genetic alterations. The association of radiomic features with genomic signatures demonstrated promising performance in predicting metastasis to the cervical lymph nodes or RET/PTC rearrangements. The effectiveness of models based on US-radiomic features in predicting BRAFV600E mutation in patients with TC requires further investigation.

Conclusion

Although this systematic review has several limitations, primarily related to the limited amount of available literature data, the association of radiomic features with genomic signatures demonstrates a potential as non-invasive tool to enhance the accuracy and efficacy of TC diagnosis and prognosis.
PROSPERO registration number: CRD42024572292.
Appendix
Available only for authorised users
Literature
1.
2.
Basolo F, Macerola E, Poma AM, Torregrossa L. The 5(th) edition of WHO classification of tumors of endocrine organs: changes in the diagnosis of follicular-derived thyroid carcinoma. Endocrine. 2023;80(3):470–6.PubMedPubMedCentralCrossRef
3.
Hadoux J, Pacini F, Tuttle RM, Schlumberger M. Management of advanced medullary thyroid cancer. Lancet Diabetes Endocrinol. 2016;4(1):64–71.PubMedCrossRef
4.
5.
6.
Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American Thyroid Association Management Guidelines for Adult patients with thyroid nodules and differentiated thyroid cancer: the american thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26(1):1–133.PubMedPubMedCentralCrossRef
7.
Yu J, Deng Y, Liu T, Zhou J, Jia X, Xiao T, et al. Lymph node metastasis prediction of papillary thyroid carcinoma based on transfer learning radiomics. Nat Commun. 2020;11(1):4807.PubMedPubMedCentralCrossRef
8.
Cibas ES, Ali SZ. The 2017 bethesda system for reporting thyroid cytopathology. Thyroid. 2017;27(11):1341–6.PubMedCrossRef
9.
Singh A, Ham J, Po JW, Niles N, Roberts T, Lee CS. The genomic landscape of thyroid cancer tumourigenesis and implications for immunotherapy. Cells. 2021;10(5):1082.PubMedPubMedCentralCrossRef
10.
Agrawal N, Akbani R, Aksoy BA, Ally A, Arachchi H, Asa SL, et al. Integrated genomic characterization of papillary thyroid carcinoma. Cell. 2014;159(3):676–90.PubMedCentralCrossRef
11.
Landa I, Cabanillas ME. Genomic alterations in thyroid cancer: biological and clinical insights. Nat Rev Endocrinol. 2024;20(2):93–110.PubMedCrossRef
12.
Grieco M, Santoro M, Berlingieri MT, Melillo RM, Donghi R, Bongarzone I, et al. PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas. Cell. 1990;60(4):557–63.PubMedCrossRef
13.
Jung CK, Little MP, Lubin JH, Brenner AV, Wells SA Jr, Sigurdson AJ, et al. The increase in thyroid cancer incidence during the last four decades is accompanied by a high frequency of BRAF mutations and a sharp increase in RAS mutations. J Clin Endocrinol Metab. 2014;99(2):E276–85.PubMedCrossRef
14.
15.
16.
17.
18.
Schlumberger M, Leboulleux S. Current practice in patients with differentiated thyroid cancer. Nat Rev Endocrinol. 2021;17(3):176–88.PubMedCrossRef
19.
Busaidy NL, Konda B, Wei L, Wirth LJ, Devine C, Daniels GA, et al. Dabrafenib Versus Dabrafenib + Trametinib in BRAF-mutated radioactive iodine refractory differentiated thyroid cancer: results of a randomized, phase 2. Open-Label Multicenter Trial Thyroid. 2022;32(10):1184–92.PubMed
20.
Chen Z, Wang W, Xu J, Song Y, Zhu H, Ma T, et al. Tumor mutation burden-assisted risk stratification for papillary thyroid cancer. Endocrine. 2022;78(2):296–305.PubMedCrossRef
21.
22.
Yan C, Huang M, Li X, Wang T, Ling R. Relationship between BRAF V600E and clinical features in papillary thyroid carcinoma. Endocr Connect. 2019;8(7):988–96.PubMedPubMedCentralCrossRef
23.
Filetti S, Durante C, Hartl D, Leboulleux S, Locati LD, Newbold K, et al. Thyroid cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up†. Ann Oncol. 2019;30(12):1856–83.PubMedCrossRef
24.
Torlontano M, Attard M, Crocetti U, Tumino S, Bruno R, Costante G, et al. Follow-up of low risk patients with papillary thyroid cancer: role of neck ultrasonography in detecting lymph node metastases. J Clin Endocrinol Metab. 2004;89(7):3402–7.PubMedCrossRef
25.
Lamartina L, Deandreis D, Durante C, Filetti S. ENDOCRINE TUMOURS: imaging in the follow-up of differentiated thyroid cancer: current evidence and future perspectives for a risk-adapted approach. Eur J Endocrinol. 2016;175(5):R185-202.PubMedCrossRef
26.
Wang H, Wei R, Liu W, Chen Y, Song B. Diagnostic efficacy of multiple MRI parameters in differentiating benign vs. malignant thyroid nodules. BMC Med Imaging. 2018;18(1):50.PubMedPubMedCentralCrossRef
27.
Klain M, Zampella E, Nappi C, Nicolai E, Ambrosio R, Califaretti E, et al. Advances in functional imaging of differentiated thyroid cancer. Cancers. 2021;13(19):4748.PubMedPubMedCentralCrossRef
28.
Zampella E, Klain M, Pace L, Cuocolo A. PET/CT in the management of differentiated thyroid cancer. Diagn Interv Imaging. 2021;102(9):515–23.PubMedCrossRef
29.
Bi WL, Hosny A, Schabath MB, Giger ML, Birkbak NJ, Mehrtash A, et al. Artificial intelligence in cancer imaging: Clinical challenges and applications. CA Cancer J Clin. 2019;69(2):127–57.PubMedPubMedCentralCrossRef
30.
Gillies RJ, Kinahan PE, Hricak H. Radiomics: images are more than pictures, they are data. Radiology. 2016;278(2):563–77.PubMedCrossRef
31.
Incoronato M, Aiello M, Infante T, Cavaliere C, Grimaldi AM, Mirabelli P, et al. Radiogenomic analysis of oncological data: a technical survey. Int J Mol Sci. 2017;18(4):805.PubMedPubMedCentralCrossRef
32.
33.
Rutman AM, Kuo MD. Radiogenomics: creating a link between molecular diagnostics and diagnostic imaging. Eur J Radiol. 2009;70(2):232–41.PubMedCrossRef
34.
35.
36.
Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Rev Esp Cardiol (Engl Ed). 2021;74(9):790–9.PubMedCrossRef
37.
38.
Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603–5.PubMedCrossRef
39.
Shea BJ, Reeves BC, Wells G, Thuku M, Hamel C, Moran J, et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ. 2017;358:j4008.PubMedPubMedCentralCrossRef
40.
Tong Y, Sun P, Yong J, Zhang H, Huang Y, Guo Y, et al. Radiogenomic analysis of papillary thyroid carcinoma for prediction of cervical lymph node metastasis: a preliminary study. Front Oncol. 2021;11:682998.PubMedPubMedCentralCrossRef
41.
Zheng T, Hu W, Wang H, Xie X, Tang L, Liu W, et al. MRI-based texture analysis for preoperative prediction of BRAF V600E mutation in papillary thyroid carcinoma. J Multidiscip Healthc. 2023;16:1–10.PubMedPubMedCentralCrossRef
42.
Wang YG, Xu FJ, Agyekum EA, Xiang H, Wang YD, Zhang J, et al. Radiomic model for determining the value of elasticity and grayscale ultrasound diagnoses for predicting BRAF(V600E) mutations in papillary thyroid carcinoma. Front Endocrinol. 2022;13:872153.CrossRef
43.
Yoon JH, Han K, Lee E, Lee J, Kim EK, Moon HJ, et al. Radiomics in predicting mutation status for thyroid cancer: a preliminary study using radiomics features for predicting BRAFV600E mutations in papillary thyroid carcinoma. PLoS ONE. 2020;15(2):e0228968.PubMedPubMedCentralCrossRef
44.
Yu J, Zhang Y, Zheng J, Jia M, Lu X. Ultrasound images-based deep learning radiomics nomogram for preoperative prediction of RET rearrangement in papillary thyroid carcinoma. Front Endocrinol. 2022;13:1062571.CrossRef
45.
Zhang R, Hu L, Cheng Y, Chang L, Dong L, Han L, et al. Targeted sequencing of DNA/RNA combined with radiomics predicts lymph node metastasis of papillary thyroid carcinoma. Cancer Imaging. 2024;24(1):75.PubMedPubMedCentralCrossRef
46.
47.
Zhang Y, Luo YK, Zhang MB, Li J, Li CT, Tang J, et al. Values of ultrasound features and MMP-9 of papillary thyroid carcinoma in predicting cervical lymph node metastases. Sci Rep. 2017;7(1):6670.PubMedPubMedCentralCrossRef
48.
Hong YR, Yan CX, Mo GQ, Luo ZY, Zhang Y, Wang Y, et al. Conventional US, elastography, and contrast enhanced US features of papillary thyroid microcarcinoma predict central compartment lymph node metastases. Sci Rep. 2015;5:7748.PubMedPubMedCentralCrossRef
49.
Sakorafas GH, Sampanis D, Safioleas M. Cervical lymph node dissection in papillary thyroid cancer: current trends, persisting controversies, and unclarified uncertainties. Surg Oncol. 2010;19(2):e57-70.PubMedCrossRef
50.
Pinker K, Shitano F, Sala E, Do RK, Young RJ, Wibmer AG, et al. Background, current role, and potential applications of radiogenomics. J Magn Reson Imaging. 2018;47(3):604–20.PubMedCrossRef
51.
Lambin P, Rios-Velazquez E, Leijenaar R, Carvalho S, van Stiphout RG, Granton P, et al. Radiomics: extracting more information from medical images using advanced feature analysis. Eur J Cancer. 2012;48(4):441–6.PubMedPubMedCentralCrossRef
52.
Cao Y, Zhong X, Diao W, Mu J, Cheng Y, Jia Z. Radiomics in differentiated thyroid cancer and nodules: explorations, application, and limitations. Cancers. 2021;13(10):2436.PubMedPubMedCentralCrossRef
53.
Affinito O, Orlandella FM, Luciano N, Salvatore M, Salvatore G, Franzese M. Evolution of intra-tumoral heterogeneity across different pathological stages in papillary thyroid carcinoma. Cancer Cell Int. 2022;22(1):263.PubMedPubMedCentralCrossRef
54.
Nikiforov YE, Steward DL, Robinson-Smith TM, Haugen BR, Klopper JP, Zhu Z, et al. Molecular testing for mutations in improving the fine-needle aspiration diagnosis of thyroid nodules. J Clin Endocrinol Metab. 2009;94(6):2092–8.PubMedCrossRef
55.
Layfield LJ, Cibas ES, Gharib H, Mandel SJ. Thyroid aspiration cytology: current status. CA Cancer J Clin. 2009;59(2):99–110.PubMedCrossRef
56.
Zhao CK, Zheng JY, Sun LP, Xu RY, Wei Q, Xu HX. BRAF(V600E) mutation analysis in fine-needle aspiration cytology specimens for diagnosis of thyroid nodules: The influence of false-positive and false-negative results. Cancer Med. 2019;8(12):5577–89.PubMedPubMedCentralCrossRef
57.
Wang Y, Ma LY, Yin XP, Gao BL. Radiomics and radiogenomics in evaluation of colorectal cancer liver metastasis. Front Oncol. 2021;11:689509.PubMedCrossRef
58.
Demetriou D, Lockhat Z, Brzozowski L, Saini KS, Dlamini Z, Hull R. The convergence of radiology and genomics: advancing breast cancer diagnosis with radiogenomics. Cancers. 2024;16(5):1076.PubMedPubMedCentralCrossRef
59.
Su GH, Xiao Y, You C, Zheng RC, Zhao S, Sun SY, et al. Radiogenomic-based multiomic analysis reveals imaging intratumor heterogeneity phenotypes and therapeutic targets. Sci Adv. 2023;9(40):eadf0837.PubMedPubMedCentralCrossRef
60.
Jiang L, You C, Xiao Y, Wang H, Su GH, Xia BQ, et al. Radiogenomic analysis reveals tumor heterogeneity of triple-negative breast cancer. Cell Rep Med. 2022;3(7):100694.PubMedPubMedCentralCrossRef
61.
Zhang Y, You C, Pei Y, Yang F, Li D, Jiang YZ, et al. Integration of radiogenomic features for early prediction of pathological complete response in patients with triple-negative breast cancer and identification of potential therapeutic targets. J Transl Med. 2022;20(1):256.PubMedPubMedCentralCrossRef
62.
Hussain S, Lafarga-Osuna Y, Ali M, Naseem U, Ahmed M, Tamez-Peña JG. Deep learning, radiomics and radiogenomics applications in the digital breast tomosynthesis: a systematic review. BMC Bioinform. 2023;24(1):401.CrossRef
63.
Bellini D, Milan M, Bordin A, Rizzi R, Rengo M, Vicini S, et al. A focus on the synergy of radiomics and RNA sequencing in breast cancer. Int J Mol Sci. 2023;24(8):7214.PubMedPubMedCentralCrossRef
64.
Gallivanone F, Bertoli G, Porro D. Radiogenomics, breast cancer diagnosis and characterization: current status and future directions. Methods Protoc. 2022;5(5):78.PubMedPubMedCentralCrossRef
65.
Grimm LJ, Mazurowski MA. Breast cancer radiogenomics: current status and future directions. Acad Radiol. 2020;27(1):39–46.PubMedCrossRef
66.
Chen L, Huang ZH, Sun Y, Domaratzki M, Liu Q, Hu P. Conditional probabilistic diffusion model driven synthetic radiogenomic applications in breast cancer. PLoS Comput Biol. 2024;20(10):e1012490.PubMedPubMedCentralCrossRef
67.
Fernandes CD, Schaap A, Kant J, van Houdt P, Wijkstra H, Bekers E, et al. Radiogenomics analysis linking multiparametric MRI and transcriptomics in prostate cancer. Cancers. 2023;15(12):3074.CrossRef
68.
69.
70.
Qureshi TA, Chen X, Xie Y, Murakami K, Sakatani T, Kita Y, et al. MRI/RNA-seq-based radiogenomics and artificial intelligence for more accurate staging of muscle-invasive bladder cancer. Int J Mol Sci. 2023;25(1):88.PubMedPubMedCentralCrossRef
71.
72.
Singh A, Chitalia R, Kontos D. Radiogenomics in brain, breast, and lung cancer: opportunities and challenges. J Med Imaging. 2021;8(3):031907.CrossRef
73.
Shui L, Ren H, Yang X, Li J, Chen Z, Yi C, et al. The era of radiogenomics in precision medicine: an emerging approach to support diagnosis, treatment decisions, and prognostication in oncology. Front Oncol. 2020;10:570465.PubMedCrossRef
74.
Zanfardino M, Castaldo R, Pane K, Affinito O, Aiello M, Salvatore M, et al. MuSA: a graphical user interface for multi-OMICs data integration in radiogenomic studies. Sci Rep. 2021;11(1):1550.PubMedPubMedCentralCrossRef
75.
Zanfardino M, Franzese M, Pane K, Cavaliere C, Monti S, Esposito G, et al. Bringing radiomics into a multi-omics framework for a comprehensive genotype-phenotype characterization of oncological diseases. J Transl Med. 2019;17(1):337.PubMedPubMedCentralCrossRef
Metadata
Title
Association of radiomic features with genomic signatures in thyroid cancer: a systematic review
Authors
Neila Luciano
Francesca Maria Orlandella
Mariantonia Braile
Carlo Cavaliere
Marco Aiello
Monica Franzese
Giuliana Salvatore
Publication date
01-12-2024
Publisher
BioMed Central
Published in
Journal of Translational Medicine / Issue 1/2024
Electronic ISSN: 1479-5876
DOI
https://doi.org/10.1186/s12967-024-05896-z

Other articles of this Issue 1/2024

Exosomes regulate SIRT3-related autophagy by delivering miR-421 to regulate macrophage polarization and participate in OSA-related NAFLD

AURKB promotes bladder cancer progression by deregulating the p53 DNA damage response pathway via MAD2L2

Standardizing digital biobanks: integrating imaging, genomic, and clinical data for precision medicine

  • Open Access
  • Review

IL-37 ameliorates myocardial fibrosis by regulating mtDNA-enriched vesicle release in diabetic cardiomyopathy mice

Overall survival prediction of gastric cancer using the gene signature of CT-detected extramural venous invasion combined with M2 macrophages infiltration

Facilitating the use of the target product profile in academic research: a systematic review

  • Open Access
  • Review

Keynote webinar | Spotlight on menopause

Menopause can have a significant impact on the body, with effects ranging beyond the endocrine and reproductive systems. Learn about the broader systemic effects of menopause, so you can help patients in your clinics through the transition.   

Prof. Martha Hickey
Dr. Claudia Barth
Dr. Samar El Khoudary
Developed by: Springer Medicine
Watch now

Keynote webinar | Spotlight on adolescent vaping

  • Live
  • Webinar | 29-01-2025 | 18:00 (CET)

Growing numbers of young people are using e-cigarettes, despite warnings of respiratory effects and addiction. How can doctors tackle the epidemic, and what health effects should you prepare to manage in your clinics?

Watch it live: Wednesday 29th January, 18:00-19:30 CET
 

Prof. Ann McNeill
Dr. Debbie Robson
Benji Horwell
Developed by: Springer Medicine
Join the webinar

Keynote webinar | Spotlight on modern management of frailty

Frailty has a significant impact on health and wellbeing, especially in older adults. Our experts explain the factors that contribute to the development of frailty and how you can manage the condition and reduce the risk of disability, dependency, and mortality in your patients.

Prof. Alfonso Cruz-Jentoft
Prof. Barbara C. van Munster
Prof. Mirko Petrovic
Developed by: Springer Medicine
Watch now

A quick guide to ECGs

Improve your ECG interpretation skills with this comprehensive, rapid, interactive course. Expert advice provides detailed feedback as you work through 50 ECGs covering the most common cardiac presentations to ensure your practice stays up to date. 

PD Dr. Carsten W. Israel
Developed by: Springer Medizin
Start the cases

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Read more
Image Credits